February 15, 2022
|
February 16, 2022
|
April 24, 2024
|
September 19, 2022
|
May 27, 2025 (Final data collection date for primary outcome measure)
|
Percentage of Participants with Clinical Remission at Week 48 [ Time Frame: Week 48 ] Percentage of participants with clinical remission at Week 48 will be reported. Clinical remission based on the modified Mayo subscores.
|
Same as current
|
|
- Percentage of Participants with Endoscopic Improvement at Week 48 [ Time Frame: Week 48 ]
Percentage of participants with endoscopic improvement at Week 48 will be reported. Endoscopic improvement at Week 48 based on the Mayo endoscopic subscore.
- Percentage of Participants with Symptomatic Remission at Week 48 [ Time Frame: Week 48 ]
Percentage of participants with symptomatic remission at Week 48 will be reported. Symptomatic remission at Week 48 based on stool and rectal bleeding symptoms.
- Percentage of Participants with Combination of Histological Remission and Endoscopic Improvement at Week 48 [ Time Frame: Week 48 ]
Percentage of participants with combination of histological remission and endoscopic improvement at Week 48 will be reported. Histologic remission and endoscopic improvement at Week 48 based on the histologic grading and the Mayo endoscopy subscore.
- Percentage of Participants with Clinical Remission at Week 24 [ Time Frame: Week 24 ]
Percentage of participants with clinical remission at Week 24 will be reported. Clinical remission based on the modified Mayo subscores
- Percentage of Participants with Adverse Events (AEs) [ Time Frame: Up to Week 48 ]
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.
- Percentage of Participants with Serious Adverse Events (SAEs) [ Time Frame: Up to Week 48 ]
A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.
- Serum Concentrations of Guselkumab Over Time [ Time Frame: Up to Week 48 ]
Serum concentrations of guselkumab over time will be reported. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive method.
- Serum Concentrations of Golimumab Over Time [ Time Frame: Up to Week 48 ]
Serum concentration of golimumab over time will be reported. Serum samples will be analyzed to determine concentrations of golimumab using a validated, specific, and sensitive method.
- Percentage of Participants with Antibodies to Guselkumab [ Time Frame: Up to Week 48 ]
Percentage of participants with antibodies to guselkumab will be reported.
- Titers of Antibodies to Guselkumab [ Time Frame: Up to Week 48 ]
Titers of antibodies to guselkumab will be reported.
- Percentage of Participants with Antibodies to Golimumab [ Time Frame: Up to Week 48 ]
Percentage of Participants with Antibodies to golimumab will be reported.
- Titers of Antibodies to Golimumab [ Time Frame: Up to Week 48 ]
Titers of antibodies to golimumab will be reported.
- Percentage of Participants with Neutralizing Antibodies to Guselkumab [ Time Frame: Up to Week 48 ]
Percentage of participants with neutralizing antibodies to guselkumab will be reported.
- Percentage of Participants with Neutralizing Antibodies to Golimumab [ Time Frame: Up to Week 48 ]
Percentage of participants with neutralizing antibodies to golimumab will be reported.
|
- Percentage of Participants with Endoscopic Improvement at Week 48 [ Time Frame: Week 48 ]
Percentage of participants with endoscopic improvement at Week 48 will be reported. Endoscopic improvement at Week 48 based on the Mayo endoscopic subscore.
- Percentage of Participants with Symptomatic Remission at Week 48 [ Time Frame: Week 48 ]
Percentage of participants with symptomatic remission at Week 48 will be reported. Symptomatic remission at Week 48 based on stool and rectal bleeding symptoms.
- Percentage of Participants with Combination of Histological Remission and Endoscopic Improvement at Week 48 [ Time Frame: Week 48 ]
Percentage of participants with combination of histological remission and endoscopic improvement at Week 48 will be reported. Histologic remission and endoscopic improvement at Week 48 based on the histologic grading and the Mayo endoscopy subscore.
- Percentage of Participants with Adverse Events (AEs) [ Time Frame: Up to Week 48 ]
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.
- Percentage of Participants with Serious Adverse Events (SAEs) [ Time Frame: Up to Week 48 ]
A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.
- Serum Concentrations of Guselkumab Over Time [ Time Frame: Up to Week 48 ]
Serum concentrations of guselkumab over time will be reported. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive method.
- Serum Concentrations of Golimumab Over Time [ Time Frame: Up to Week 48 ]
Serum concentration of golimumab over time will be reported. Serum samples will be analyzed to determine concentrations of golimumab using a validated, specific, and sensitive method.
- Percentage of Participants with Antibodies to Guselkumab [ Time Frame: Up to Week 48 ]
Percentage of participants with antibodies to guselkumab will be reported.
- Titers of Antibodies to Guselkumab [ Time Frame: Up to Week 48 ]
Titers of antibodies to guselkumab will be reported.
- Percentage of Participants with Antibodies to Golimumab [ Time Frame: Up to Week 48 ]
Percentage of Participants with Antibodies to golimumab will be reported.
- Titers of Antibodies to Golimumab [ Time Frame: Up to Week 48 ]
Titers of antibodies to golimumab will be reported.
- Percentage of Participants with Neutralizing Antibodies to Guselkumab [ Time Frame: Up to Week 48 ]
Percentage of participants with neutralizing antibodies to guselkumab will be reported.
- Percentage of Participants with Neutralizing Antibodies to Golimumab [ Time Frame: Up to Week 48 ]
Percentage of participants with neutralizing antibodies to golimumab will be reported.
|
Not Provided
|
Not Provided
|
|
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy.
|
Not Provided
|
Interventional
|
Phase 2
|
Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment
|
Colitis, Ulcerative
|
- Biological: Guselkumab
Guselkumab will be administered as subcutaneous injection.
- Biological: Golimumab
Golimumab will be administered as subcutaneous injection.
- Biological: JNJ-78934804
JNJ-78934804 will be administered subcutaneously as per defined regimen.
- Drug: Placebo
Placebo will be administered as subcutaneous injection.
|
- Placebo Comparator: Group 1: Placebo
Participants will receive placebo subcutaneously (SC). All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
Intervention: Drug: Placebo
- Experimental: Group 2: Guselkumab
Participants will receive guselkumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
Intervention: Biological: Guselkumab
- Experimental: Group 3: Golimumab
Participants will receive golimumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
Intervention: Biological: Golimumab
- Experimental: Group 4: JNJ-78934804 (High-dose)
Participants will receive JNJ-78934804 dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
Intervention: Biological: JNJ-78934804
- Experimental: Group 5: JNJ-78934804 (Mid-dose)
Participants will receive JNJ-78934804 dose regimen 2 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
Intervention: Biological: JNJ-78934804
- Experimental: Group 6: JNJ-78934804 (Low-dose)
Participants will receive JNJ-78934804 dose regimen 3 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
Intervention: Biological: JNJ-78934804
|
Not Provided
|
|
Recruiting
|
550
|
500
|
October 10, 2029
|
May 27, 2025 (Final data collection date for primary outcome measure)
|
Inclusion Criteria:
- Confirmed diagnosis of ulcerative colitis (UC) for at least 3 months prior to baseline
- Moderately to severely active UC as assessed by the modified Mayo Score
- Demonstrated inadequate response, loss of response, or intolerance to at least one biologic or novel oral with biologic-like activity
- If female and of childbearing potential, must meet the contraception and reproduction requirements
Exclusion Criteria:
- Has severe extensive colitis as defined in the protocol
- Extent of inflammatory disease limited to the rectum
- Participants with current diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease (CD)
- Has a history of, or ongoing, chronic or recurrent infectious disease, including but not limited to, sinopulmonary infections, bronchiectasis, recurrent renal/urinary tract infections (example, pyelonephritis, cystitis), an open, draining, or infected skin wound, or an ulcer
- Currently has a malignancy or a history of malignancy within 5 years before screening (with the exception of nonmelanoma skin cancer or cervical carcinoma in situ that has been treated with no evidence of recurrence within 12 months of first dose of study intervention)
|
Sexes Eligible for Study: |
All |
|
18 Years to 65 Years (Adult, Older Adult)
|
No
|
|
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Jordan, Korea, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
|
Lithuania, Mexico, Serbia, Turkey
|
|
NCT05242484
|
CR109179 78934804UCO2001 ( Other Identifier: Janssen Research & Development, LLC ) 2021-005528-39 ( EudraCT Number )
|
Yes
|
Studies a U.S. FDA-regulated Drug Product: |
Yes |
Studies a U.S. FDA-regulated Device Product: |
No |
|
Plan to Share IPD: |
Yes |
Plan Description: |
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu |
URL: |
https://www.janssen.com/clinical-trials/transparency |
|
Janssen Research & Development, LLC
|
Same as current
|
Janssen Research & Development, LLC
|
Same as current
|
Not Provided
|
Study Director: |
Janssen Research & Development, LLC Clinical Trial |
Janssen Research & Development, LLC |
|
Janssen Research & Development, LLC
|
April 2024
|